A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non-squamous non-small-cell lung cancer.
LanQing HuoChu ChuXiaoBo JiangShiYang ZhengPengXin ZhangRui ZhouNaiBin ChenJinYu GuoBo QiuHui LiuPublished in: Cancer medicine (2023)
This pilot study met its goal of demonstrating the tolerability of consolidation bevacizumab after hypo-CCRT. Further investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC is warranted, while the potential for grade 3 respiratory toxicities should be taken into consideration.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- metastatic colorectal cancer
- squamous cell carcinoma
- radiation therapy
- phase ii study
- small cell lung cancer
- brain metastases
- high grade
- open label
- advanced non small cell lung cancer
- tyrosine kinase
- low grade
- respiratory tract
- human health
- risk assessment
- climate change